Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:2871 |
| Name | endometrial carcinoma |
| Definition | A endometrial cancer that is located_in the tissue lining the uterus. |
| Source | DiseaseOntology.org |
| Alt Ids | DOID:3000 |
| Xrefs |
SNOMEDCT_US_2023_03_01:30289006 |
SNOMEDCT_US_2023_03_01:93781006
|
| Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer uterine cancer endometrial cancer endometrial carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| MSH2 loss | N/A | endometrial carcinoma | not applicable | detail... |
| FGFR2 N549K | FIIN-1 | endometrial carcinoma | sensitive | detail... |
| FGFR2 K310R FGFR2 N549K | FIIN-1 | endometrial carcinoma | sensitive | detail... |
| FGFR2 wild-type | FIIN-1 | endometrial carcinoma | resistant | detail... |
| FGFR2 S252W | RO4987655 | endometrial carcinoma | decreased response | detail... |
| FGFR2 N549K | RO4987655 | endometrial carcinoma | no benefit | detail... |
| FGFR2 K310R FGFR2 N549K | RO4987655 | endometrial carcinoma | no benefit | detail... |
| FGFR2 N549K | RO5126766 | endometrial carcinoma | no benefit | detail... |
| FGFR2 K310R FGFR2 N549K | RO5126766 | endometrial carcinoma | no benefit | detail... |
| FGFR2 S252W | Selumetinib | endometrial carcinoma | decreased response | detail... |
| FGFR2 N549K | Selumetinib | endometrial carcinoma | no benefit | detail... |
| FGFR2 K310R FGFR2 N549K | Selumetinib | endometrial carcinoma | no benefit | detail... |
| FGFR2 S252W | RO5126766 | endometrial carcinoma | sensitive | detail... |
| PIK3CA R88L PIK3CA E453del PIK3CA T1052K PTEN loss PTEN mut | Copanlisib | endometrial carcinoma | sensitive | detail... |
| FGFR2 S252W | GSK3052230 | endometrial carcinoma | sensitive | detail... |
| MLH1 mutant | N/A | endometrial carcinoma | not applicable | detail... |
| MSH2 mutant | N/A | endometrial carcinoma | not applicable | detail... |
| MSH6 mutant | N/A | endometrial carcinoma | not applicable | detail... |
| PIK3CA mutant | Copanlisib | endometrial carcinoma | no benefit | detail... |
| TP53 mutant | Adavosertib | endometrial carcinoma | predicted - sensitive | detail... |
| PTEN negative | Olaparib | endometrial carcinoma | no benefit | detail... |
| PTEN negative | Buparlisib | endometrial carcinoma | sensitive | detail... |
| PTEN negative | Buparlisib + Olaparib | endometrial carcinoma | sensitive | detail... |
| PTEN del | Olaparib | endometrial carcinoma | no benefit | detail... |
| PTEN del | Buparlisib | endometrial carcinoma | sensitive | detail... |
| PTEN del | Buparlisib + Olaparib | endometrial carcinoma | sensitive | detail... |
| PTEN del STK11 del | Buparlisib + Olaparib | endometrial carcinoma | sensitive | detail... |
| PTEN del STK11 del | Olaparib | endometrial carcinoma | no benefit | detail... |
| PTEN del STK11 del | Buparlisib | endometrial carcinoma | predicted - sensitive | detail... |
| MLH1 negative | Pembrolizumab | endometrial carcinoma | sensitive | detail... |
| PMS2 negative | Pembrolizumab | endometrial carcinoma | sensitive | detail... |
| MSH2 negative | Pembrolizumab | endometrial carcinoma | sensitive | detail... |
| MSH6 negative | Pembrolizumab | endometrial carcinoma | sensitive | detail... |
| MSH6 negative | Dostarlimab-gxly | endometrial carcinoma | sensitive | detail... |
| MSH2 negative | Dostarlimab-gxly | endometrial carcinoma | sensitive | detail... |
| PMS2 negative | Dostarlimab-gxly | endometrial carcinoma | sensitive | detail... |
| MLH1 negative | Dostarlimab-gxly | endometrial carcinoma | sensitive | detail... |
| MLH1 negative | Nivolumab | endometrial carcinoma | sensitive | detail... |
| PMS2 negative | Nivolumab | endometrial carcinoma | sensitive | detail... |
| MSH2 negative | Nivolumab | endometrial carcinoma | sensitive | detail... |
| MSH6 negative | Nivolumab | endometrial carcinoma | sensitive | detail... |
| MLH1 negative | Avelumab | endometrial carcinoma | sensitive | detail... |
| PMS2 negative | Avelumab | endometrial carcinoma | sensitive | detail... |
| MSH2 negative | Avelumab | endometrial carcinoma | sensitive | detail... |
| MSH6 negative | Avelumab | endometrial carcinoma | sensitive | detail... |
| RET fusion | Selpercatinib | endometrial carcinoma | sensitive | detail... |
| MLH1 negative | Tislelizumab | endometrial carcinoma | sensitive | detail... |
| MLH1 negative | Retifanlimab | endometrial carcinoma | sensitive | detail... |
| PMS2 negative | Retifanlimab | endometrial carcinoma | sensitive | detail... |
| MSH2 negative | Retifanlimab | endometrial carcinoma | sensitive | detail... |
| MSH6 negative | Retifanlimab | endometrial carcinoma | sensitive | detail... |
| MSH6 negative | Tislelizumab | endometrial carcinoma | sensitive | detail... |
| MSH2 negative | Tislelizumab | endometrial carcinoma | sensitive | detail... |
| PMS2 negative | Tislelizumab | endometrial carcinoma | sensitive | detail... |
| POLE inact mut | N/A | endometrial carcinoma | not applicable | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT00492778 | Phase II | Cisplatin | Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer | Unknown status | USA | CAN | 0 |
| NCT00996892 | Phase I | Cobimetinib + Pictilisib | Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
| NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Recruiting | USA | 0 |
| NCT01440998 | Phase I | Carboplatin + Dasatinib + Paclitaxel | Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | Completed | USA | 0 |
| NCT01504126 | Phase I | Propranolol | Beta-Blocker / Ovarian | Completed | USA | 0 |
| NCT01888562 | Phase I | Ponatinib | Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma | Withdrawn | 0 | |
| NCT01935973 | Phase II | Trametinib Trametinib + Uprosertib | Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer | Completed | USA | 0 |
| NCT02059265 | Phase II | Dasatinib | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer | Terminated | USA | 0 |
| NCT02065687 | Phase III | Carboplatin + Metformin + Paclitaxel Carboplatin + Paclitaxel | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | Unknown status | USA | 0 |
| NCT02117817 | Phase I | Buparlisib + Nab-paclitaxel | Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer | Withdrawn | 0 | |
| NCT02228681 | Phase II | Tamoxifen Medroxyprogesterone Everolimus + Letrozole | Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer | Completed | USA | 0 |
| NCT02397083 | Phase II | Everolimus | Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT02454972 | Phase II | Lurbinectedin | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | Completed | USA | SWE | ITA | GBR | FRA | ESP | DEU | CHE | BEL | 0 |
| NCT02549209 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Pembro/Carbo/Taxol in Endometrial Cancer | Completed | USA | 0 |
| NCT02549989 | Phase II | LY3023414 | Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer | Completed | USA | 0 |
| NCT02558348 | Phase Ib/II | Anlotinib | Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) | Terminated | USA | 0 |
| NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Completed | USA | ITA | FRA | ESP | DEU | CHE | 0 |
| NCT02628067 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Active, not recruiting | 0 | |
| NCT02725268 | Phase II | Paclitaxel Sapanisertib Sapanisertib + Serabelisib | Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer | Completed | USA | NOR | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUS | 0 |
| NCT02807844 | Phase Ib/II | MCS110 + Spartalizumab | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | FIN | ESP | DEU | CHE | BEL | 3 |
| NCT02977195 | Phase I | NP137 | First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors (NP137) | Completed | FRA | 0 |
| NCT03008408 | Phase II | Everolimus + Letrozole + Ribociclib | Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT03015129 | Phase II | Durvalumab Durvalumab + Tremelimumab | A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer | Completed | USA | 0 |
| NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
| NCT03077698 | Phase II | Megestrol acetate + Sodium cridanimod | An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer | Terminated | USA | 0 |
| NCT03138408 | Phase I | SC-004 Budigalimab + SC-004 | SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers | Terminated | USA | 0 |
| NCT03192059 | Phase II | Aspirin + Cyclophosphamide + Pembrolizumab + Vitamin D | Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer (PRIMMO) | Completed | BEL | 0 |
| NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Active, not recruiting | POL | NZL | FRA | ESP | AUS | 4 |
| NCT03241745 | Phase II | Nivolumab | A Study of Nivolumab in Selected Uterine Cancer Patients | Completed | USA | 0 |
| NCT03319628 | Phase I | XMT-1536 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | Active, not recruiting | USA | 0 |
| NCT03367741 | Phase II | Cabozantinib + Nivolumab Nivolumab | Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT03476798 | Phase II | Bevacizumab + Rucaparib | Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium | Completed | USA | 0 |
| NCT03517449 | Phase III | Lenvatinib + Pembrolizumab Paclitaxel Doxorubicin | Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) | Completed | USA | TUR | POL | NZL | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG | 6 |
| NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
| NCT03526432 | Phase II | Atezolizumab + Bevacizumab | Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT03603184 | Phase III | Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel | Atezolizumab Trial in Endometrial Cancer - AtTEnd (AtTEnd) | Completed | NZL | ITA | GBR | ESP | DEU | CHE | AUT | AUS | 3 |
| NCT03660826 | Phase II | Olaparib Cediranib + Olaparib | Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT03686124 | Phase Ib/II | IMA-203 | ACTengine IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (ACTengine) | Recruiting | USA | DEU | 0 |
| NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Completed | USA | 0 |
| NCT03836157 | Phase II | Bevacizumab + Mirvetuximab Soravtansine | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | Withdrawn | USA | 0 |
| NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Completed | USA | 0 |
| NCT03884101 | Phase III | Carboplatin + Paclitaxel Lenvatinib + Pembrolizumab | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) | Completed | USA | TUR | POL | ITA | ISR | IRL | GBR | ESP | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 7 |
| NCT03909152 | Phase II | Onapristone Anastrozole + Onapristone | A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone | Completed | USA | 0 |
| NCT03914612 | Phase III | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | Active, not recruiting | USA | CAN | 3 |
| NCT03917381 | Phase Ib/II | Acasunlimab | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | Active, not recruiting | USA | TUR | POL | ITA | ISR | HUN | ESP | CZE | 2 |
| NCT03926936 | Phase II | Fulvestrant | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study (FUCHSia) | Completed | NLD | BEL | 0 |
| NCT03932409 | Phase I | Pembrolizumab | Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer (FIERCE) | Active, not recruiting | USA | 0 |
| NCT03955978 | Phase I | Dostarlimab-gxly | TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT04014530 | Phase Ib/II | Pembrolizumab + PTC124 | Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study (ATAPEMBRO) | Recruiting | NLD | 0 |
| NCT04065269 | Phase II | Ceralasertib + Olaparib Ceralasertib | ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI) | Active, not recruiting | GBR | CAN | 0 |
| NCT04104776 | Phase Ib/II | Enzalutamide + Tulmimetostat Tulmimetostat | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | Recruiting | USA | POL | ITA | GBR | FRA | ESP | 1 |
| NCT04106414 | Phase II | Nivolumab Linrodostat + Nivolumab | Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment | Active, not recruiting | USA | 0 |
| NCT04152499 | Phase Ib/II | Sacituzumab tirumotecan | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) | Active, not recruiting | USA | TUR | CAN | 3 |
| NCT04205630 | Phase II | Trastuzumab Duocarmazine | SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma | Completed | USA | POL | 5 |
| NCT04235101 | Phase I | Niraparib + Trastuzumab Duocarmazine | Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors | Completed | NLD | GBR | BEL | 0 |
| NCT04251416 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma | Active, not recruiting | USA | 0 |
| NCT04269200 | Phase III | Durvalumab Durvalumab + Olaparib Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Olaparib + Paclitaxel Carboplatin + Paclitaxel | Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E) | Active, not recruiting | USA | POL | LTU | ISR | HUN | GRC | EST | ESP | DEU | CAN | BRA | BEL | AUS | 9 |
| NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
| NCT04450901 | Phase I | YBL-006 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | Unknown status | AUS | 2 |
| NCT04469764 | Phase II | Abemaciclib + Anastrozole Abemaciclib + Letrozole Abemaciclib | Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer | Recruiting | USA | 0 |
| NCT04486352 | Phase Ib/II | Atezolizumab + Talazoparib Atezolizumab + Ipatasertib Abemaciclib + Giredestrant Inavolisib + Letrozole | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer (EndoMAP) | Recruiting | USA | 0 |
| NCT04513665 | Phase II | Zanidatamab | ZW25 in Women With Endometrial Cancers | Completed | USA | 0 |
| NCT04634877 | Phase III | Carboplatin + Paclitaxel Cisplatin + Paclitaxel Carboplatin + Docetaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Docetaxel + Pembrolizumab Cisplatin + Docetaxel Carboplatin + Docetaxel + Pembrolizumab | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | Active, not recruiting | USA | TUR | SWE | POL | NOR | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUT | ARG | 9 |
| NCT04652076 | Phase Ib/II | Carboplatin + NP137 + Paclitaxel Trevatide + Pembrolizumab NP137 + Pembrolizumab Carboplatin + NP137 + Paclitaxel Carboplatin + Paclitaxel | GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab (GYNET) | Active, not recruiting | FRA | 0 |
| NCT04678908 | Phase I | HB0025 | A Study of Injection HB0025 in Patients With Advanced Solid Tumors | Unknown status | USA | 1 |
| NCT04719273 | Phase II | Anastrozole + Onapristone | Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT04795661 | Phase II | Pembrolizumab | Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP) | Active, not recruiting | FRA | 0 |
| NCT04906382 | Phase I | Carboplatin + Paclitaxel + Tislelizumab | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | Terminated | USA | 0 |
| NCT05032040 | Phase II | XmAb20717 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | Active, not recruiting | USA | 0 |
| NCT05036681 | Phase II | Futibatinib + Pembrolizumab | A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma | Terminated | USA | 0 |
| NCT05043714 | Phase I | NG-641 + Nivolumab | Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) | Completed | USA | GBR | 0 |
| NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
| NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | IRL | ESP | CAN | AUS | 2 |
| NCT05143970 | Phase I | IPH5301 IPH5301 + Paclitaxel + Trastuzumab | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES) | Recruiting | FRA | 0 |
| NCT05154487 | Phase II | Alpelisib + Fulvestrant | A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT05156268 | Phase II | Olaparib + Pembrolizumab | A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma | Active, not recruiting | USA | 0 |
| NCT05173987 | Phase III | Cisplatin + Docetaxel Carboplatin + Docetaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Pembrolizumab | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | Active, not recruiting | USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | ISR | IRL | HUN | GBR | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | 6 |
| NCT05194072 | Phase I | SGN-B7H4V | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | Terminated | USA | GBR | ESP | DEU | CAN | 0 |
| NCT05255653 | Phase II | Olaparib Medroxyprogesterone Carboplatin Megestrol acetate Paclitaxel Cisplatin Durvalumab | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) | Recruiting | NLD | GBR | FRA | CAN | 0 |
| NCT05300048 | Phase I | Serabelisib Nab-paclitaxel + Serabelisib | Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations | Completed | USA | 0 |
| NCT05378425 | Phase I | NTX-1088 NTX-1088 + Pembrolizumab | A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | Recruiting | USA | POL | ISR | 0 |
| NCT05542407 | Phase I | Atezolizumab + Dordaviprone | ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | Recruiting | USA | 0 |
| NCT05548296 | Phase II | Prexasertib Gemcitabine + Prexasertib | A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Recruiting | USA | ITA | FRA | ESP | DEU | 0 |
| NCT05564377 | Phase II | Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Recruiting | USA | 1 |
| NCT05603910 | Phase I | Lenvatinib + Pembrolizumab | Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma | Recruiting | USA | 0 |
| NCT05714553 | Phase Ib/II | Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Terminated | GBR | 0 |
| NCT05795595 | Phase Ib/II | CTX131 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | Completed | USA | 0 |
| NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Terminated | USA | ESP | AUS | 1 |
| NCT05949424 | FDA approved | Lenvatinib Olaparib Pazopanib Palbociclib Sunitinib | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults (OPTI-DOSE) | Unknown status | NLD | 0 |
| NCT05958199 | Phase I | NPX267 | Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 | Suspended | USA | 0 |
| NCT05983432 | Phase I | BL-B01D1 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | Recruiting | USA | ITA | FRA | ESP | 1 |
| NCT06046274 | Phase II | Acasunlimab + Pembrolizumab | GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer | Withdrawn | USA | ITA | ESP | DNK | BEL | 1 |
| NCT06132958 | Phase III | Paclitaxel Doxorubicin Nab-paclitaxel Sacituzumab tirumotecan | Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) (TroFuse-005) | Active, not recruiting | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
| NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | NOR | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
| NCT06384807 | Phase Ib/II | BHV-1510 BHV-1510 + Cemiplimab | A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06444815 | Phase I | VET3-TGI Pembrolizumab + VET3-TGI | A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001) | Recruiting | USA | 0 |
| NCT06481592 | Phase II | Aldesleukin + Lifileucel Cyclophosphamide + Fludarabine | A Study of Lifileucel (tumor-infiltrating Lymphocytes) in Adults with Advanced Endometrial Cancer. | Recruiting | USA | 0 |
| NCT06486441 | Phase III | Doxorubicin Paclitaxel Sacituzumab govitecan-hziy | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) (ASCENT-GYN-01) | Active, not recruiting | USA | POL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUS | 6 |
| NCT06660654 | Phase II | Raludotatug deruxtecan | A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) | Recruiting | USA | ITA | FRA | ESP | DNK | BEL | 3 |
| NCT06712472 | Phase III | Olaparib | Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for P53abn Endometrial Cancer (RAINBO-RED) | Recruiting | FRA | 0 |
| NCT06746116 | Phase III | Durvalumab + Olaparib Carboplatin + Durvalumab + Paclitaxel | A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain (DUoENDE) | Active, not recruiting | ESP | 0 |
| NCT06880549 | Phase I | mRNA-4106 mRNA-4106 + Nivolumab and relatlimab-rmbw | A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors | Active, not recruiting | USA | 0 |
| NCT06952504 | Phase III | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Sacituzumab tirumotecan Carboplatin + Docetaxel + Pembrolizumab Pembrolizumab + Sacituzumab tirumotecan | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) (TroFuse-033) | Recruiting | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 10 |
| NCT06979596 | Phase II | Megestrol acetate Tamoxifen Exemestane Dexamethasone + Fludrocortisone + ODM-208 Fulvestrant Letrozole | A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | Recruiting | USA | TUR | GBR | ESP | CAN | BRA | ARG | 6 |
| NCT06989112 | Phase III | Carboplatin + Docetaxel + Pembrolizumab Pembrolizumab + Trastuzumab deruxtecan Carboplatin + Paclitaxel + Pembrolizumab AZD2936 + Trastuzumab deruxtecan | DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (DE-01) | Recruiting | USA | SWE | POL | NOR | NLD | ITA | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUT | AUS | 4 |
| NCT07022483 | Phase III | Carboplatin + Paclitaxel Trastuzumab deruxtecan | Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer | Recruiting | USA | 4 |
| NCT07044336 | Phase III | AZD8205 Paclitaxel Doxorubicin | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | Recruiting | USA | SVN | POL | NLD | LTU | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 5 |
| NCT07070232 | Phase Ib/II | BNT327 + YL202 YL202 Itraconazole + YL202 | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Recruiting | USA | ITA | GBR | ESP | DEU | BEL | AUS | 0 |
| NCT07186842 | Phase Ib/II | BNT329 | A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 | Recruiting | USA | GBR | ESP | 0 |
| NCT07209449 | Phase II | Elacestrant Abemaciclib + Elacestrant | A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer | Recruiting | USA | 0 |
| NCT07223424 | Phase II | Pembrolizumab Nivolumab | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune) | Recruiting | USA | 0 |
| NCT07335497 | Phase Ib/II | CR-001 | CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors (ASCEND) | Recruiting | USA | 0 |
| NCT07444814 | Phase I | HWK-007 | Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT07470853 | Phase I | HWK-016 Bevacizumab + HWK-016 | A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. | Recruiting | USA | 0 |